Table 4.
Table of Type of Oral Antibiotics Used
| Antibiotic Class and Dosing | Primary Outcome (Microbiologic Failure at 90 days) | Self-reported Adherence Abstracted from Medical Record through Chart Review | ||
|---|---|---|---|---|
| Self-reported Adherence | Self-reported Nonadherence | No Adherence Data Available | ||
| Beta-lactamsa | 0/8 (0%) | 6 | 1 | 1 |
| Clindamycin 450 mg QID | 1/3 (33%) | 2 | 0 | 1 |
| Doxycycline 100 mg BID | 6/37 (16%) | 23 | 5 | 9 |
| Ciprofloxacin 750 mg BID | 0/2 (0%) | 1 | 0 | 1 |
| Linezolid 600 mg BID | 3/15 (20%) | 9 | 2 | 4 |
| Rifampinb 450 mg BID | 1/3 (33%) | 1 | 1 | 1 |
| Trimethoprim-sulfamethoxazole 2 DS BID | 4/26 (15%) | 15 | 4 | 7 |
| Comparison of dual- vs single-antibiotic class therapy | ||||
| Single-agent therapy | 7/52 (13%) | 33 | 3 | 16 |
| Dual-agent therapyc | 4/21 (19%) | 12 | 5 | 4 |
Abbreviations: BID, twice per day; DS, double strength; QID, 4 times per day.
Includes amoxicillin-clavulanate 875 mg BID, cephalexin 500 mg QID, cefadroxil 1000 mg BID, and dicloxacillin 1000 mg QID.
Rifampin was never used as single-agent therapy.
Patients who received dual-agent therapy are listed for both categories.